Pharma IP teams don’t get many “heads up” moments. But Russia’s patent-term extension landscape is one of those areas where a small procedural change can quietly become a big commercial problem—fast.
Here’s the agitation: if you’re relying on assumptio…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Most drug patent portfolios are built like insurance policies—file early, hope for broad coverage, and assume the courtroom will sort out the details.
But …

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical market, “patent expiration” isn’t just a legal milestone. It’s a pricing event. It’s a supply-chain inflection point. It’s a formulary strategy momen…

Generic launches don’t “just happen.” They’re engineered by timelines.
If you’re still forecasting generic drug launch dates using spreadsheets, historical averages, or gut feel, you’re already behind. In branded pharma, timing is strategy. In generi…

Most people “read” the FDA Orange Book. The best people mine it.
If you’re in pharma BD, licensing, investing, or competitive intelligence, you already know the Orange Book is more than a regulatory directory—it’s a map of where IP value is likely to b…

Biotech R&D is awash in metrics—NPV, IRR, probability-weighted forecasts, “strategic fit,” pipeline heat maps. But most portfolio reviews still devolve into a familiar debate: Which projects are the most important?
Here’s the uncomfortable truth:…

Biopharma is entering a talent cliff—and it’s happening before most teams even realize they’re standing at the edge.
The “patent cliff” is usually discussed in terms of revenue: blockbuster drugs lose exclusivity, generics rush in, and forecasts get re…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Overstocking branded drugs isn’t just a balance-sheet problem—it’s a cash-flow cliff.
In today’s pharmaceutical supply chain, the risk isn’t theoretical. It…

Big Pharma’s “patent cliff” isn’t just a revenue story—it’s a workforce story.
When blockbuster exclusivity ends, the market doesn’t simply swap one drug for another. It forces a rapid reallocation of capital, attention, and headcount across R&D, c…

Biosimilar sourcing is no longer a procurement exercise—it’s an IP strategy.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part isn’t finding a supplier. It’s knowing when you can safely switch, what you might s…